Sharon Deveson Kell

• 

Lenvatinib plus pembrolizumab for advanced kidney cancer

By Sharon Deveson Kell|2024-01-18T08:54:41+00:0018 Jan 2024|Drug treatments|

The final survival information from the phase 3 CLEAR study [...]

Read More

Comments Off on Lenvatinib plus pembrolizumab for advanced kidney cancer

• 

Patient’s perspective on pembrolizumab/lenvatinib for kidney cancer

By Sharon Deveson Kell|2024-01-16T15:43:53+00:0016 Jan 2024|Drug treatments|

In 2009, Cesar Fuentes was first diagnosed with kidney cancer [...]

Read More

Comments Off on Patient’s perspective on pembrolizumab/lenvatinib for kidney cancer

• 

METEOR study: Cabozantinib compared to everolimus in advanced kidney cancer

By Sharon Deveson Kell|2024-01-09T16:10:37+00:009 Jan 2024|Drug treatments|

Cabozantinib is a tyrosine kinase inhibitor that is used [...]

Read More

Comments Off on METEOR study: Cabozantinib compared to everolimus in advanced kidney cancer

• 

‘No stupid questions’ for newly diagnosed kidney cancer patients

By Sharon Deveson Kell|2024-01-09T09:46:55+00:009 Jan 2024|Patient advocacy|

In this recent video interview, Dr Rachel Giles, chief executive [...]

Read More

Comments Off on ‘No stupid questions’ for newly diagnosed kidney cancer patients

• 

FDA approves belzutifan for advanced kidney cancer

By Sharon Deveson Kell|2024-04-19T08:00:25+00:0018 Dec 2023|Drug treatments|

The Food and Drug Administration (FDA) in the United States [...]

Read More

Comments Off on FDA approves belzutifan for advanced kidney cancer

• 

Cancer signs on urinal mats in pubs and football grounds

By Sharon Deveson Kell|2023-12-11T14:53:53+00:0011 Dec 2023|Cancer news|

The NHS are putting urinal mats in public places in [...]

Read More

Comments Off on Cancer signs on urinal mats in pubs and football grounds

• 

Belzutifan for advanced kidney cancer: long-term follow-up

By Sharon Deveson Kell|2024-11-21T09:24:59+00:0030 Nov 2023|Drug treatments|

Studies looking at the genes of people with kidney cancer have shown [...]

Read More

Comments Off on Belzutifan for advanced kidney cancer: long-term follow-up

• 

NICE Annual Conference

By Sharon Deveson Kell|2023-11-30T09:30:59+00:0029 Nov 2023|Patient advocacy|

Sharon Deveson Kell attended the National Institute for Health and [...]

Read More

Comments Off on NICE Annual Conference

• 

Longer better lives: A manifesto for cancer research and care

By Sharon Deveson Kell|2023-11-29T09:55:25+00:0028 Nov 2023|Patient advocacy|

Today Cancer Research UK is publishing ‘Longer, better lives: A manifesto [...]

Read More

Comments Off on Longer better lives: A manifesto for cancer research and care

• 

ESMO 2023: New online educational programme for kidney cancer nurses

By Sharon Deveson Kell|2023-11-27T13:50:41+00:0027 Nov 2023|Patient advocacy|

Action Kidney Cancer have been involved with the development of [...]

Read More

Comments Off on ESMO 2023: New online educational programme for kidney cancer nurses